Application of autologous derived-platelet rich plasma gel in the treatment of chronic wound ulcer: Diabetic foot ulcer

Journal of Extra-Corporeal Technology

Volumn 42, Issue 1, 2010, Pages 20-29

  Akingboye, Akinfemi Ayobami ^a,c   Giddins, Stephen ^b   Gamston, Philip ^b   Tucker, Arthur ^b   Navsaria, Harshad ^a   Kyriakides, Constantions ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Autologous derived platelet rich plasma; Diabetic foot ulcer; Growth factors; Wound healing

Indexed keywords

ANGIOGENIC FACTOR; BETA CATENIN; COLLAGENASE; CONNECTIVE TISSUE GROWTH FACTOR; ELASTASE; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GLYCOPROTEIN IB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GROWTH FACTOR; KERATIN; KERATINOCYTE GROWTH FACTOR; LEUKOCYTE ELASTASE; MATRIX METALLOPROTEINASE; PHOSPHOLIPASE A2; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SOMATOMEDIN; SORBITOL; THROMBOCYTE CONCENTRATE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANTIBIOTIC THERAPY; ATHEROSCLEROTIC PLAQUE; BLOOD; BLOOD BANK; BLOOD CLOTTING; BLOOD VESSEL OCCLUSION; BLOOD VESSEL PERMEABILITY; BONE MARROW; CELL CYCLE; CELL DAMAGE; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC WOUND; CYTOKINE PRODUCTION; DEBRIDEMENT; DIABETIC FOOT; DISEASE PREDISPOSITION; ELASTICITY; ENDOTHELIUM CELL; ENZYMATIC DEGRADATION; EPITHELIZATION; GEL; GENE EXPRESSION; GLYCATION; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; IMMUNOPATHOLOGY; INFLAMMATION; INJURY; KERATINOCYTE; LIMB SALVAGE; MACROPHAGE ACTIVATION; MEGAKARYOCYTE; MITOSIS; NEUROPATHY; NUTRIENT AVAILABILITY; ONCOGENE C MYC; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RECURRENT DISEASE; REVIEW; SOFT TISSUE; STEM CELL; SWEATING; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOCYTE RICH PLASMA; THROMBOCYTE STRUCTURE; TISSUE OXYGENATION; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION; VON WILLEBRAND DISEASE; WOUND CARE; WOUND HEALING; WOUND INFECTION;

EID: 77950803154     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist, J. The global burden of diabetic foot disease. Lancet. 2005;366:1719-1724. (Pubitemid 41587452)
2. Ragnarson Tennvall G, Apelqvist J. Health-economic consequence of diabetic foot lesion. Clin Infect Dis. 2004:39:S132-9.
3. Abbott CA, Carrington AL, Ashe H, et al. The Northwest Diabetes Foot Care Study: Incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002; 19:377-384.
4. Abbott CA, Vileikyte L, Williamson S, Carrington AL, Boulton AJM. Multicentre study of the incidence of and predictive factors for diabetic neuropathic foot ulcers. Diabetes Care. 1998;21:1071-1075. (Pubitemid 28368510)
5. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217-228. (Pubitemid 40095873)
6. Shearer A, Schuffham P, Gordiois A, Ogleshy A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the US. Diabetes Care. 2003;26:2305-2310. (Pubitemid 36993317)
7. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care. 1983;6:87-91. (Pubitemid 13144888)
8. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917-932.
9. Saar WE, Lee TH, Berlet GC. Economic burden of diabetic foot and ankle disorder. Foot Ankle Int. 2005;26:27-31. (Pubitemid 40070883)
10. Consensus development of conference in diabetic foot wound care. 7-8 April 1999, Boston, Massachusetts, American Diabetes Association. J Am Podiatr Med Assoc. 1999;89:475-483.
11. Sheehan P, Jones P, Caseli A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12 week prospective trial. Diabetes Care. 2003;26: 1879-1882. (Pubitemid 36929137)
12. Robson MC, Thomason A, Pierce GF, Philips LG, Robson LE. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet. 1992;339:23-25.
13. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathway for incident lower extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22:157-162. (Pubitemid 29028314)
14. Shaw JE, van Schie CH, Carrington AL, Abbott CA, Boulton AJ. An analysis of dynamic forces transmitted through the foot in diabetic neuropathy. Diabetes Care. 1998;2:1955-1959.
15. Steel DL, Donohoe D, Webster MW, Lindsley L; Diabetic Ulcer Study Group. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg. 1996;183:61-64. (Pubitemid 26234895)
16. Nwomeh BC, Liang HX, Cohen IK, Yager DR. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res. 1999;81:189-195.
17. He Z, King GL. Micro vascular complication of diabetes. Endocrinol Metab Clin North Am. 2004;33:215-258.
18. Bucalo B, Eaglstein WH, Falanga V. Inhibition of cell proliferation by chronic wound fluid. Wound Repair Regen. 1993;1:181-186.
19. Bennett NF, Schultz GS. Growth factors and wound healing. Part 11: Role in normal and chronic wound healing. Am J Surg. 1993;166: 74-81. (Pubitemid 23281429)
20. Yager DR, Nwomeh BC. The proteolytic environment of chronic wounds. Wound Repair Regen . 1999;7:433-441.
21. Palolahti M, Lauharanta J, Vaheri A. et al. Proteolytic activity of leg ulcer exudates. Exp Dermatol. 1993;2:29-37. (Pubitemid 23244485)
22. Chen SM, Ward SI, Olutoye OO, Diegelmann RF, Kelman CI. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Rep Regen. 1997;5:23-32.
23. Morasso MI, Tomic-Canic M. Epidermal stem cells, the cradle of epidermal determination and wound healing. Biol Cell. 2005;97:173-183.(Pubitemid 40360890)
24. Waikel RL, Kawachi Y, Waikel PA, Wana XJ, Roop DR. Deregulation expression of c-myc depletes epidermal stem cells. Nat Genet. 2001;28:165-168. (Pubitemid 32538063)
25. Arnold I, Watt FM. c-myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny. Curr Biol. 2001;11:558-568. (Pubitemid 32324758)
26. Stojadinovic O, Brem H, Tomi-Canic M, et al. Molecular pathogenesis of chronic wounds: The role of β catenin and c-myc in the inhibition of epithelialization and wound healing. Am J Pathol. 2005;167: 59-69. (Pubitemid 40884770)
27. Gandarillas A, Watt FM. c-Myc promotes differentiation of human epidermal stem cells. Genes Dev. 1997;11:2869-2882. (Pubitemid 27481687)
28. Oster SK, Marhin WW, Asker C, et al. Myc is an essential negative regulator of platelet-derived growth factor beta receptor expression. Mol Cell Biol. 2000;20:6768-6778.
29. Wang Y, He H, Zigler JS Jr, et al. bFGF suppresses serum-deprivation- induced apoptosis in a human lens epithelia cell line. Exp Cell Res. 1999;249:123-130. (Pubitemid 29394031)
30. Izadnegahdar MF, Rathanasiwami P, Shah RM. Effects of EGF and TGF beta-1 myc gene expression and DNA synthesis in embryonic hamster palate mesenchyme cells. Anat Rec. 1999;254:453-464.
31. Alder SC, Kent KJ. Enhancing wound healing with growth factors. Facial Plast Surg Clin North Am. 2002;10:129-146.
32. Steel DL. The Diabetic Ulcer Study Group: Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetics ulcers. J Vasc Surg. 1995;21:71-81.
33. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomised placebo-controlled study. Diabetic Care. 1998;21:822-827.
34. Everts PA, Knape JT, Weibrich, et al. Platelet-rich plasma and platelet gel: A review. J Extra Corpor Technol. 2006;38:174-187.
35. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth (VEGF) and its receptors. FASEB J.1999;13:9.
36. Lawrence W, Diegelmann R. Growth factors in wound healing. Clin Dermatol. 1994;12:157-169.
37. Grotendorst G, Soma Y, Takehara K, et al. EGF and TGF-alpha are potent chemo attractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J Cell Physiol. 1989;139:617-623. (Pubitemid 19167836)
38. McGee G, Davidson JM, Buckley A, et al. Recombinant basic fibroblast growth factor accelerates wound healing. J Surg Res. 1998;45: 145-153.
39. Cross K, Mustoe T. Growth factors in wound healing. Surg Clin North Am. 2003;83:531-545.
40. Beer H, Gassmann M, Munz B, et al. Expression and function of keratinocyte growth and activin in skin morphogenesis and cutaneous wound repair. J Investig Dermatol Symp Proc. 2000;5:34-39. (Pubitemid 32044087)
41. Massague J. The TGF-beta family of growth and differentiation factors. Cell. 1987;49:437-438.
42. Wahl S, Hunt D, Wakefield L, et al. Transforming growth factor type beta induces monocyte chemo taxis and growth factor production. Proc Natl Acad Sci USA. 1987;84:5788.
43. Sporn MB, Roberts AB, Wakefield L, et al. Transforming growth factors- beta: Biological function and chemical structure. Science. 1986; 233:532-534. (Pubitemid 16019904)
44. Edwards DR, Murphy G, Reynolds JJ, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J. 1987;6:1899-1904.
45. Bassols A, Massague J. Transforming growth factor beta regulates the expression and structure of extracellular matrix chondroitin/dermatan sulphate proteoglycans. J Biol Chem. 1988;263:3039-3045. (Pubitemid 18062962)
46. Fukamizu J, Grinnell F. Spatial organization of extracellular matrix and fibroblast activity: Effects of serum, TGF-beta and fibronectin. Exp Cell Res. 1990;190:276-282.
47. Guler HP, Zapf J, Scheiwiller E, Friesch ER. Recombinant human insulin-like growth I stimulate growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA. 1988;85:4889-4893.
48. Grant M, Jerdan J, Merimere T. Insulin-like growth factor-I modulate endothelial cell chemotaxis. J Clin Endocrinol Metab. 1987;65:370-371. (Pubitemid 17103028)
49. Kubota S, Kawata K, Yanagita T, Doi H, Kitoh T, Takigawa M. Abundant retention and release of connective tissue growth factor (CTGF/CCN2) by platelets. J. Biochem. 2004;136:279-282. (Pubitemid 39545786)
50. Cooper DM, Yu EZ, Hennessey P, Ko F, Robson MC. Determination of endogenous cytokines in chronic wounds. Ann Surg. 1994;219: 688-691.
51. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factors analysis from platelet-rich plasma: Implications for wound healing. Plast Reconstr Surg. 2004;114:1502-1508. (Pubitemid 40361959)
52. Marx RE. Platelet-rich plasma (PRP): What is PRP and what is not PRP? Implant Dent. 2001;10:225-228.
53. Weibrich G, Kleis WK, Hafner G, et al. Growth factor levels in platelet- rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg. 2002;30:97-102. (Pubitemid 34846492)
54. Marx RE. Platelet-rich platelet plasma: Evidence to support its use. J Oral Maxillofac Surg. 2004;62:489-496. (Pubitemid 38451232)
55. Anitua E, Andia I, Ardanza B, et al. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4-15. (Pubitemid 38111215)
56. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler ER. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg. 1986;204:322-330.
57. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler EM, Ceira F. Stimulation of repair in chronic, non-healing cutaneous ulcers using platelet-derived wound healing formula. Sur Gynecol Obstet. 1990;170:56-60. (Pubitemid 20048058)
58. Ganio C, Tenewitz FE, Wilson RC, Moyles BG. The treatment of chronic non-healing wounds using autologous platelet-derived growth factors. J Foot Ankle Surg. 1993;32:263-268. (Pubitemid 23199758)
59. Fohn M, Bannasch H. Artificial skin. Methods Mol Med. 2007;140: 167-182
60. Trent JF, Kirsner RS. Tissue engineered skin; Apligraf, a bilayered living skin equivalent. Int J Clin Pract. 1998;52:408-413.
61. Stark HJ, Willhank MJ, Mirancea N, et al. Authentic fibroblast matrix in dermal matrix in dermal matrix equivalents normalises epidermal histogenesis and dermoepider mal junction in organotypic co-culture. Eur J Cell Biol. 2004;83:631-645. (Pubitemid 40123828)
62. Veves A, Falanga V, Armstrong DG, Sabolinski ML. Apligraf Diabetic Foot Ulcer Study. Graft skin, a human skin equivalent, is effective in the management of non-infected neuro pathic diabetic foot ulcers. A prospective randomised multicentre clinical trial. Diabetic Care. 2001;24:290-295.
63. Christie RJ, Carrington L, Alving B. Post operative bleeding induced by topical bovine thrombin: Report of cases. Surgery. 1997;121:708-710. (Pubitemid 27251912)
64. Grant WP, Jerlin EA, Pietrzak WS, et al. The utilization of autologous growth factors for the facilitation of fusion in complex neuropathic fractures in diabetic population. Clin Podiatr Med Surg. 2005;22: 561-584.
65. Driver VR, Hanft J, Fylling CP, Beriou JM. Autologous Diabetic Foot Ulcer Study Group. A prospective randomised, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic. Ostomy Wound Manage. 2006;52:68-74.
66. Cassidy LK, Finney AS, Ellis WC, Spiwak AJ, Riley JB. Quantifying platelet gel coagulation using Sonoclot and Thrombelastograph hemostasis analyser. J Extra Corpor Technol. 2005;37:48-51.